Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study

Figure 3 Hepatitis B surface antigen seroconversion rate. A: Per protocol analysis showed that the rate of hepatitis B surface antigen seroconversion in 48-wk peg-IFN add-on group was significantly higher than monotherapy group at weeks 48 and 72 (^bP < 0.001 vs monotherapy group at week 48; ^dP < 0.001 vs monotherapy group at week 72). Week 0 was defined as the time when the patients were enrolled in this study for patients in the monotherapy group; B: Intention-to-treatment analysis showed that the rate of hepatitis B surface antigen seroconversion in 48-wk peg-IFN add-on group was significantly higher than rate in monotherapy group at weeks 48 and 72 (^bP < 0.001 vs monotherapy group at week 48; ^dP < 0.001 vs monotherapy group at week 72). Week 0 was defined as the time when the patients were enrolled in this study for patients in the monotherapy group. HBsAg: Hepatitis B surface antigen.